RxDoctor Payments Data

Melissa Torres, NP

Adult Health · Albuquerque, NMNPI 1932653417

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 60 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $664 and has fallen 51.9% since, to $319 in 2025.

$1,560in general payments, 2019–2025

Across 60 payments — averaging $25.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$355
  • Genmab U.S., Inc.$221
  • Myriad Women's Health, Inc.$220
  • Merck$144
  • Eisai Inc.$112
  • Astellas Pharma US Inc$93
  • plus $415 from 9 others

What the payments were for

  • Food & beverage$1,560100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,560 in reported general payments places this provider in the 75th percentile of 52 adult health providers in New Mexico.

See all adult health providers in New Mexico

Medicare billing

Part B allowed, 2024
$159,833
Medicare patients
105
Services billed
9,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol65$5,885
PremarinEstrogens, Conjugated11$5,579
Oxycodone Hcl18$703
ProgesteroneProgesterone, Micronized17$502
Gabapentin26$486
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen23$291
Levothyroxine Sodium14$149
Lorazepam18$130
Ciprofloxacin Hcl14$128
Fluconazole19$121
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav14$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCLevothyroxine Sodium$85$14914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 52 adult health providers in New Mexico.

Other adult health in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →